All In Biotech

Drug Trial Radar · NCT07825025

The Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation

A Multicenter, Randomized, Double-blind, Positive-control, Non-inferiority Clinical Trial on the Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Dec 5, 2025

Primary completion

Apr 9, 2028

Study completion Apr 9, 2028

Sponsor

Lead sponsor
Zhongnan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To verify the effectiveness and safety of the HCA-N solution in actual clinical preservation, this study intends to conduct a prospective, randomized, and positive control clinical trial. Using the classic HTK solution as a reference, the study will focus on evaluating the performance of the HCA-N solution in terms of the incidence of delayed recovery of transplant kidney function and the speed of early renal function recovery, with the aim of providing better preservation solution selection and high-level evidence-based guidance for clinical practice in kidney transplantation.

Conditions

  • Kidney Transplant

Interventions

  • HCA-N SolutionDrug

    Experimental Group using HCA-N Solution for the preservation of donor kidneys in renal transplantation

  • HTK SolutionDrug

    control group using HTK Solution in kidney organ transplantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects experiencing delayed graft function (DGF) post-transplantation.Time frame: Baseline at Days 1, 3, 7, 14, and 28 post-transplantation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.